| P50 | author | Antonio Ieni | Q57108994 |
| P2093 | author name string | G Tuccari | |
| | L Rigoli | |
| | R A Caruso | |
| | V Barresi | |
| P2860 | cites work | Adverse prognosis of clustered‐cell versus single‐cell micrometastases in pN0 early gastric cancer | Q82215561 |
| | Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections | Q82547098 |
| | HER2 expression and its clinicopathological features in resectable gastric cancer | Q83629811 |
| | Early gastric cancer of signet ring cell carcinoma is more amenable to endoscopic treatment than is early gastric cancer of poorly differentiated tubular adenocarcinoma in select tumor conditions | Q83845498 |
| | The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen | Q83858971 |
| | Neutrophil-rich gastric carcinoma in the integrated cancer registry of eastern Sicily, Italy | Q86431090 |
| | Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status | Q87492670 |
| | Lymph node metastasis in early gastric cancer | Q87764156 |
| | The Vienna classification of gastrointestinal epithelial neoplasia | Q24669885 |
| | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 |
| | Genetic instabilities in human cancers | Q28131826 |
| | Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 |
| | HER2 testing in gastric cancer: a practical approach | Q28256814 |
| | Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer | Q33239677 |
| | Gastric dysplasia: the Padova international classification | Q33841698 |
| | Pathology of gastric intestinal metaplasia: clinical implications | Q33954445 |
| | TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma | Q34044864 |
| | HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature | Q34223664 |
| | HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. | Q34324291 |
| | A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease | Q34486941 |
| | Mitochondrial DNA alterations in the progression of gastric carcinomas: unexplored issues and future research needs | Q34552088 |
| | Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. | Q34554455 |
| | Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer | Q34613504 |
| | HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer | Q34638138 |
| | Early HER2 dysregulation in gastric and oesophageal carcinogenesis | Q58003579 |
| | [Incidence of stomach cancer is decreasing faster in the Centre-North of Italy] | Q59503887 |
| | Gastritis OLGA-staging & gastric cancer risk: a twelve year clinico-pathological follow-up study | Q61884190 |
| | HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods | Q64018932 |
| | The pathogenesis of gastric carcinoma--epidemiologic pathology of precursor lesions (author's transl) | Q67818081 |
| | Gastric cancer in Colombia. II. Case-control epidemiologic study of precursor lesions | Q68215171 |
| | Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast | Q68481028 |
| | Strategy for lymphadenectomy of gastric cancer | Q69583667 |
| | Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer | Q69926364 |
| | Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia | Q72718181 |
| | Allelotype of adenoma and differentiated adenocarcinoma of the stomach | Q73027868 |
| | c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems | Q73829259 |
| | Long-term prognosis of gastric cancer in a European country: a population-based study in Florence (Italy). 10-year survival of cases diagnosed in 1985-1987 | Q74439213 |
| | Lymph node metastasis in early gastric cancer: a clinicopathological analysis | Q74807683 |
| | Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer | Q75306492 |
| | Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay | Q77925384 |
| | Significance of lymphatic invasion on regional lymph node metastasis in early gastric cancer using LYVE-1 immunohistochemical analysis | Q79404830 |
| | Risk factors for lymph node metastasis in undifferentiated early gastric cancer | Q80106722 |
| | Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery | Q80362861 |
| | Antioxidant vitamin supplementation and control of gastric cancer | Q80467009 |
| | Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndrome | Q80523471 |
| | Predicting lymph node metastases in early gastric cancer: radical resection or organ-sparing therapy? | Q82116766 |
| | Patterns of expression of trefoil peptides and mucins in gastric polyps with and without malignant transformation | Q42605220 |
| | Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. | Q43254569 |
| | Gastric cancer: trastuzumab trial results spur search for other targets. | Q43276334 |
| | A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases | Q43694077 |
| | Early gastric cancer: follow-up after gastrectomy in 159 patients | Q43998519 |
| | Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer | Q44764084 |
| | Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas | Q44867167 |
| | Are biopsy specimens predictive of HER2 status in gastric cancer patients? | Q44885327 |
| | BRAF/K-ras mutation, microsatellite instability, and promoter hypermethylation of hMLH1/MGMT in human gastric carcinomas | Q45199687 |
| | Comparative analysis of protein expressions in primary and metastatic gastric carcinomas | Q46331500 |
| | Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis | Q46670276 |
| | Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer | Q46755338 |
| | Approaching heterogeneity of human epidermal growth factor receptor 2 in surgical specimens of gastric cancer | Q47673066 |
| | Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. | Q48001325 |
| | Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype. | Q49061414 |
| | Dysregulation of the E-cadherin/catenin complex by irreversible mutations in human carcinomas. | Q49087476 |
| | HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance. | Q50993984 |
| | Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer. | Q51006230 |
| | Genetics of gastric cancer. | Q51219045 |
| | Regional estimates of stomach cancer burden in Italy. | Q51735485 |
| | HER-2 amplification is highly homogenous in gastric cancer. | Q51779078 |
| | HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. | Q52848050 |
| | Precursor-derived versus de-novo carcinogenesis depends on lineage-specific mucin phenotypes of intramucosal gland-forming gastric neoplasms. | Q53090343 |
| | Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. | Q53128686 |
| | Epithelial dysplasia of the stomach with gastric immunophenotype shows features of biological aggressiveness. | Q53232176 |
| | Genetic aspects of gastric cancer instability. | Q53270206 |
| | [Studies of promoter methylation status and protein expression of E-cadherin gene in associated progression stages of gastric cancer]. | Q53379095 |
| | CDX2 expression in the intestinal-type gastric epithelial neoplasia: frequency and significance. | Q53494631 |
| | Adenomatous and foveolar gastric dysplasia: distinct patterns of mucin expression and background intestinal metaplasia. | Q53548396 |
| | HER2/neu over-expression predicts poor outcome in early gastric cancer without lymph node metastasis. | Q54325866 |
| | Letter to the Editor regarding the paper by Aurilio et al., A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. | Q54380131 |
| | Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. | Q54497269 |
| | Clinicopathologic characteristics and outcomes of gastric cancers with the MSI-H phenotype. | Q54500848 |
| | HER2 status in unusual histological variants of gastric adenocarcinomas. | Q54551587 |
| | Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. | Q54559293 |
| | Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. | Q54574338 |
| | Low frequency of HER2 amplification and overexpression in early onset gastric cancer. | Q54605374 |
| | Correlation of c-erbB-2, EGF and EGFR expression with postoperative survival of patients with advanced carcinoma of the stomach. | Q54777268 |
| | Targeted therapy with trastuzumab in dysplasia and adenocarcinoma arising in Barrett's esophagus: a translational approach. | Q54784146 |
| | Gastric cancer: Classification, histology and application of molecular pathology | Q34642023 |
| | Differential gene expression profiling of gastric intraepithelial neoplasia and early-stage adenocarcinoma | Q34750616 |
| | Discordance rate of HER2 status in primary gastric carcinomas and synchronous lymph node metastases: a multicenter retrospective analysis | Q34834419 |
| | Impression of prognosis regarding pathologic stage after preoperative chemoradiotherapy in rectal cancer | Q34932625 |
| | Clinicopathologic factors and molecular markers related to lymph node metastasis in early gastric cancer | Q34954681 |
| | Prevalence of Precancerous Conditions and Gastric Cancer Based upon the National Cancer Screening Program in Korea for 7 Years, Single Center Experience | Q34997278 |
| | Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma | Q35006904 |
| | HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily. | Q35047997 |
| | HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. | Q35111575 |
| | Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry | Q35385639 |
| | HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis | Q35538755 |
| | Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology. | Q35670454 |
| | Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma | Q35700713 |
| | Molecular basis of gastric cancer development and progression | Q35821348 |
| | HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study. | Q35893399 |
| | Indefinite for non-invasive neoplasia lesions in gastric intestinal metaplasia: the immunophenotype | Q35954338 |
| | Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis | Q35963767 |
| | Gastric-type well-differentiated adenocarcinoma and pyloric gland adenoma of the stomach | Q36585160 |
| | Gastric precancerous changes: carcinogenesis, clinical behaviour immunophenotype study and surveillance. | Q36585709 |
| | Pathology and molecular biology of gastric cancer | Q36601939 |
| | HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population | Q36849324 |
| | Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients | Q37135262 |
| | Assessment of a HER2 scoring system for gastric cancer: results from a validation study | Q37142266 |
| | HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target | Q37149210 |
| | Gastric adenocarcinoma incidence in the province of Messina (Insular Italy): A cancer registry study | Q37575145 |
| | Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes | Q37607824 |
| | HER2 testing in gastric cancer | Q37822236 |
| | Discovery of biomarkers for gastric cancer: a proteomics approach | Q38002306 |
| | Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis | Q38122908 |
| | Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study | Q38964573 |
| | Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients | Q39038837 |
| | The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis | Q39160504 |
| | HER-2/neu amplification is an independent prognostic factor in gastric cancer. | Q40303656 |
| | Gastric precancerous process in a high risk population: cohort follow-up | Q41186775 |
| | Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation | Q41932946 |
| | Gastric cancer in Colombia. I. Cancer risk and suspect environmental agents | Q42131938 |
| | HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing | Q42431264 |
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Erb-b2 receptor tyrosine kinase 2 | Q415271 |
| | stomach neoplasm | Q4335552 |
| | tumor biomarker | Q66205818 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 234851 | |
| P577 | publication date | 2015-10-01 | |
| P1433 | published in | Disease Markers | Q15756044 |
| P1476 | title | HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach | |
| P478 | volume | 2015 | |